New York City Audience Applauds Speech By Cannabis Science CEO Dr. Robert Melamede at 'The Marijuana Conference;' CFO Richard Cowan on Panel Moderated by CNBC Anchor Trish Regan for New Program to Air In Early December Also Covered By Discovery Channel and National Geographic
COLORADO SPRINGS, Colo., Oct. 27 /PRNewswire/ -- Cannabis Science, Inc. (OTC Bulletin Board: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to report that the audience at "the first non-biased event in the industry" loudly cheered the speech by Cannabis Science CEO Dr. Robert Melamede. The Marijuana Conference (www.TheMarijuanaConference.com) was organized by Dealflow, and was attended by over two hundred investors and cannabis entrepreneurs.
Richard Cowan, Cannabis Science CFO Richard Cowan was on a panel discussion titled "Entrepreneurial Vision: The Business of Marijuana", moderated by CNBC Anchor Trish Regan whose "Marijuana Inc" has been the most watched program on the network. A sequel hosted by Regan is scheduled to air early in December. Film crews from Discovery Channel and National Geographic also filmed the conference for documentaries about the industry.
Although the conference was "all business" the audience enthusiastically applauded the speech by Dr. Melamede about why marijuana is unlike any other drug because of its ability to very broadly stimulate the endocannabinoid system that homeostatically and holistically regulates all of our body systems. As a result, cannabis can safely and effectively treat many different illnesses with huge health benefits while at the same time providing huge potential savings in medical costs. Dr Melamede, in fact, develops the logic that cannabis is an essential nutrient for modern man and is, in effect, an anti-aging agent. Historical use, modern peer-reviewed science and the results medical marijuana users are getting will eventual overcome the stagnation of government policy driven by ignorance and special interests.
Dr. Melamede commented, "The investment community is very open-minded about the importance of cannabis in health care reform. I was very pleased by the warm reception we received."
Richard Cowan commented, "The conference was a great success and we salute Dealflow for their foresight in organizing the event. Wall Street is well ahead of Washington, as usual."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
SOURCE Cannabis Science, Inc.
More by this Source
Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Company's Drug Development Pipeline
May 29, 2013, 13:51 ET
Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
Apr 26, 2013, 09:28 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.